BDBM139540 US10189849, staurosporine::US10307427, Staurosporine::US10329300, Staurosporine::US11091485, Compound Staurosporine::US11542261, Compound staurosporine::US11814388, Compound Staurosporine::US20230312583, Compound staurosporine::US20240025908, Example Staurosporine::US20240246972, Compound Staurosporine::US8889696, Staurosporine::US9051313, Staurosporine::US9586965, Control Staurosporine
SMILES CN[C@@H]1CC2OC([C@@H]1OC)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13
InChI Key InChIKey=YISMQBFJYDFMAL-UHFFFAOYSA-N
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 86 hits for monomerid = 139540
Affinity DataIC50: 104nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 1.28E+3nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 3.57nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 148nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 299nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 1.94E+3nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 0.996nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.00900nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 0.356nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 0.623nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Tyk Medicines
US Patent
Tyk Medicines
US Patent
Affinity DataIC50: 500nMAssay Description:1) The compound solution and the positive control were diluted 8.3 times with double distilled water and then added to the 384 well plate, each conce...More data for this Ligand-Target Pair
Affinity DataIC50: 33.4nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 2.67nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 0.808nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 22.6nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 174nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
Affinity DataKd: 440nMAssay Description:Compounds 2-9 were evaluated in an ADP detection assay externally using the Kinomescan KdELECT platform from Discover X.More data for this Ligand-Target Pair
TargetcAMP-dependent protein kinase catalytic subunit alpha(Human)
Avicenna Biosciences, Inc.
US Patent
Avicenna Biosciences, Inc.
US Patent
Affinity DataIC50: 0.678nMAssay Description:Compounds as a powder were dissolved in dimethyl sulfoxide to make a 10 mM stock. Compounds were tested in 10-dose IC50 triplicate mode with a 3-fold...More data for this Ligand-Target Pair
Affinity DataIC50: 0.884nMAssay Description:Compounds as a powder were dissolved in dimethyl sulfoxide to make a 10 mM stock. Compounds were tested in 10-dose IC50 triplicate mode with a 3-fold...More data for this Ligand-Target Pair
Affinity DataIC50: 0.627nMAssay Description:Compounds as a powder were dissolved in dimethyl sulfoxide to make a 10 mM stock. Compounds were tested in 10-dose IC50 triplicate mode with a 3-fold...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 6.18nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 1nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 3.54nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Spiny starfish)
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 2.63nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Affinity DataIC50: 0.984nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 1.56nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Affinity DataIC50: 1.55nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
Affinity DataIC50: 0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Affinity DataKd: 240nMAssay Description:Compounds 2-9 were evaluated in an ADP detection assay externally using the Kinomescan KdELECT platform from Discover X.More data for this Ligand-Target Pair
Affinity DataKd: 120nMAssay Description:Compounds 2-9 were evaluated in an ADP detection assay externally using the Kinomescan KdELECT platform from Discover X.More data for this Ligand-Target Pair
Affinity DataIC50: 2.11nMAssay Description:Inhibition of protein kinase activity by compounds was carried out on the Radio-tagged HotSpot kinase experimental platform of Reaction Biology Corpo...More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Inhibition of protein kinase activity by compounds was carried out on the Radio-tagged HotSpot kinase experimental platform of Reaction Biology Corpo...More data for this Ligand-Target Pair
Affinity DataIC50: 0.246nMAssay Description:Inhibition of protein kinase activity by compounds was carried out on the Radio-tagged HotSpot kinase experimental platform of Reaction Biology Corpo...More data for this Ligand-Target Pair
TargetCDK-activating kinase assembly factor MAT1/Cyclin-H/Cyclin-dependent kinase 7(Human)
Tyk Medicines
US Patent
Tyk Medicines
US Patent
Affinity DataIC50: 50nMAssay Description:1) The compound solution and the positive control were diluted 8.3 times with double distilled water and then added to the 384 well plate, each conce...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 62.2nMAssay Description:The compound of Example 39, 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one, was subjected to a kinase...More data for this Ligand-Target Pair
Affinity DataIC50: 4.66nMAssay Description:The compound of Example 39, 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one, was subjected to a kinase...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:The compound of Example 39, 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one, was subjected to a kinase...More data for this Ligand-Target Pair
Affinity DataIC50: 243nMAssay Description:The compound of Example 39, 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one, was subjected to a kinase...More data for this Ligand-Target Pair
TargetCalcium/calmodulin-dependent protein kinase type II subunit gamma(Human)
Temple University
US Patent
Temple University
US Patent
Affinity DataIC50: 0.700nMAssay Description:The compound of Example 39, 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one, was subjected to a kinase...More data for this Ligand-Target Pair
Affinity DataIC50: 3.64nMAssay Description:The compound of Example 39, 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one, was subjected to a kinase...More data for this Ligand-Target Pair
Affinity DataIC50: 4.01nMAssay Description:The compound of Example 39, 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one, was subjected to a kinase...More data for this Ligand-Target Pair